

Atrioventricular Nodal Reentry Tachycardia (AVNRT)
Atrioventricular Nodal Reentry Tachycardia (AVNRT)
Melvin M. Scheinman, M.D., F.A.C.P.
University of California, San Francisco, School of Medicine
Definition/Key Clinical Features
Differential Diagnosis
Best Tests
Best Therapy
Best References
Definition/Key Clinical Features
- AVNRT is the most common form of supraventricular tachycardia;
it results from conduction through a reentrant circuit comprising fast and
slow atrioventricular nodal pathways
- Heart rate, 150–250 beats/min
- Neck pounding
- Palpitations, light-headedness, near-syncope
- Narrow QRS complexes on ECG
- Abrupt onset and termination of episodes
- More common in women than in men
- Frequently presents after 20 yr of age
Differential Diagnosis
- Atrial fibrillation
- Atrial flutter
- AV reentrant tachycardia
Best Tests
- 12-lead ECG
- The P wave is either buried within the QRS complex
or inscribed just after the QRS complex
- The P wave inscribed by retroconduction over the AV
node is negative in the inferior leads and positive in lead V1; PSVT may manifest
as small negative deflections in the inferior leads and a small positive deflection
in V1 (pseudo r¹ pattern)
Best Therapy
Acute Therapy
Nonpharmacologic
Pharmacologic
- Adenosine: for use when carotid massage fails to convert
SVT
- Possible adverse effects: headache, wheezing, flushing,
which will disappear within 45–60 sec; atrial, ventricular, and
junctional premature beats; atrial fibrillation in 3% to 5% of cases,
which may result in serious problems for patients with accessory pathways
- An external defibrillator should be readily available
when adenosine is administered
- Dose: initial dose: rapid bolus of 6 mg I.V., followed
by a saline flush; if necessary, a 12 mg dose and finally an 18 mg dose
can be given
- Metoprolol (5 mg I.V.) or verapamil (0.1 mg/kg I.V.)
for patients who fail to respond to adenosine
Long-term Therapy
- Associated with frequent recurrences and adverse effects
Pharmacologic
- Beta blockers
- Sotalol
- Common side effects: torsade de pointes, heart failure,
bradycardia, exacerbation of chronic obstructive or bronchospastic lung
disease
- Adjust dose for renal function and QT-interval response
during in-hospital initiation phase
- Dose: 240–320 mg/day
- Cost/mo: $138
- Calcium channel blockers (verapamil, diltiazem)
- Digoxin
- Dose: 0.1 mg/day
- Cost/mo: $9
- Antiarrhythmic agents: for patients without structural
cardiac disease; more effective than beta blockers and calcium channel blockers,
but with 25% to 35% recurrence rates
- Amiodarone
- Common side effects: photosensitivity, pulmonary
toxicity, polyneuropathy, GI upset, bradycardia, torsade de pointes (rare),
hepatic toxicity, thyroid dysfunction
- Dose: 100–400 mg/day
- Cost/mo: $94
- Disopyramide
- Common side effects: torsade de pointes, heart failure,
glaucoma, urinary retention, dry mouth
- Dose: 400–750 mg/day
- Cost/mo: $84
- Dofetilide
- Common side effect: torsade de pointes
- Dose: 500–1,000 mg/day
- Cost/mo: N/A
- Flecainide
- Common side effects: ventricular tachycardia, heart
failure, enhanced AV nodal conduction (conversion to atrial flutter)
- Dose: 200–300 mg/day
- Cost/mo: $115
- Procainamide
- Common side effects: torsade de pointes, lupuslike
syndrome, GI symptoms
- Dose: 1,000–4,000 mg/day
- Cost/mo: $59
- Propafenone
- Common side effects: ventricular tachycardia, heart
failure, enhanced AV nodal conduction (conversion to atrial flutter)
- Dose: 490–900 mg/day
- Cost/mo: $198
- Quinidine
- Common side effects: torsade de pointes, GI upset,
enhanced AV nodal conduction
- Dose: 600–1,500 mg/day
- Cost/mo: $67
- Single-dose agents for p.r.n. use: diltiazem, 120 mg,
or propranolol, 80 mg; p.r.n. dosing regimens are used with caution and only
after efficacy and safety have been established for the individual patient
under ECG monitoring
Nonpharmacologic
- Catheter ablation
- Procedure of choice for patients in whom drug therapy
fails and those with milder symptoms who prefer to avoid long-term drug
therapy
-
- Success rate > 96%
- AV block occurs in ~ 1% of patients
Best References
Kwaku KF, et al: Card Electophysiol Rev 6:414, 2002
Jackman WM, et al: N Engl J Med 327:313, 1992
October 2004
© 2011 Decker Intellectual Properties. All rights reserved.